

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-2. (cancelled)

3. (Original) A pharmaceutical composition for the treatment of deep vein thrombosis comprising a nucleic acid ligand to a β_3 integrin and a pharmaceutically acceptable excipient.

4. (Original) A method for detecting a deep vein thrombosis in an individual, the method comprising:

- (a) providing a nucleic acid ligand to a β_3 integrin, said nucleic acid ligand conjugated to a radioactive label;
- (b) administering said nucleic acid ligand to said individual;
- (c) detecting the site of said thrombosis by analyzing the localization of said nucleic acid ligand using a radioimaging technique.

5. (Original) An anti-clotting composition for use in acute coronary syndromes and percutaneous coronary intervention, the composition comprising a nucleic acid ligand to a β_3 integrin and a pharmaceutically-acceptable excipient.

6-7. (cancelled)